“…There exist numerous methods of potential value for detecting antibodies to tumor antigens in xenogeneic antisera prepared against cellular antigens (Ting and Herberman, 1976;Herberman, 1977). The array of technologies employed previously includes cytotoxicity (Schultz et al, 1975;Fritz e et al, 1976, Rosenberg et al, 1977, complement fixation (Lewis et al, 1969;Wood and Barth, 1974;Sabin and Tarro, 1973;Hollinshead et al, 1976;Rogers et al, 1977), isotopic antiglobulin binding assays (Harder and MacKhann, 1968;Sparks et al, 1969), immunofluorescence (Henle and Henle, 1966;Moller, 1961;McCoy et al, 1974) and antibody-dependent cellular cytoxicity (Perlman et al, 1972;Jolley et al, 1976). The discovery by Kronvall et al, (1970) that Staphylococcus aureus protein A (SPA can bind the Fc portion of several mammalian species of IgG provided the basis for development of new immunoassays to detect IgG antibodies and cellular antigens.…”